Document is current

Article History

Received: 25 October 2024

Accepted: 24 May 2025

First Online: 21 June 2025

Declarations

:

: This study was approved by the Research Ethics Committee of Tabriz University of Medical Sciences, Tabriz, Iran (IR.TBZMED.PHARMACY.REC.1402.002), and then registered in with the clinical trial ID of IRCT20231017059748 N1. The research protocol is designed under the Declaration of Helsinki and later revisions of ethical principles for medical research. All respective institutional review boards and regulatory authorities reviewed and approved the protocol before registration. The researchers will explain the trial protocol and any related modifications in detail to patients, their trustees, or their guardians. At the beginning of the study, a modified version of the World Health Organization’s (WHO) informed consent form template will be used to obtain written informed consent for participation by HH. Ethical consent forms will be completed for all participants before the study. Also, consent for participants’ biological specimen collection will be obtained for the quantification of procalcitonin and IL-6 serum levels.

: There will be no personal identifying information published.

: The authors declare that they have no competing interests.